CCXI ChemoCentryx Inc.

40.74
-1.78  -4%
Previous Close 42.52
Open 42.53
Price To Book 38.43
Market Cap 2,373,861,420
Shares 58,268,567
Volume 639,211
Short Ratio
Av. Daily Volume 1,458,918
Stock charts supplied by TradingView

NewsSee all news

  1. ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital

    MOUNTAIN VIEW, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc.

  2. ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference

    MOUNTAIN VIEW, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan

  3. ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference

    MOUNTAIN VIEW, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper

  4. VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA Associated Vasculitis

    Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity Improved

  5. ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA-Associated Vasculitis

    -- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --   -- Significantly reduced glucocorticoid toxicity -- --

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2Q 2020.
CCX140 - LUMINA-1
Focal Segmental Glomerulosclerosis
Phase 1b early response data released September 1, 2016. Noted 29% overall survival data when combined with FOLFIRINOX - January 22, 2017.
CCX872
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 2016.
CCX168
Atypical Hemolytic Uremic Syndrome (aHUS)
Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn's disease
Phase 3 data met primary endpoints - November 25, 2019.
Avacopan - CCX168 (ADVOCATE)
Associated vasculitis (AAV)
Phase 2b data due in 3Q 2020.
Avacopan -AURORA
Hidradenitis Suppurativa (HS)
Phase 2 data due in 2020.
Avacopan - CCX168
C3 glomerulopathy (C3G)
Phase 2 data due 2020.
CCX140 - LUMINA-2
Focal Segmental Glomerulosclerosis and Nephrotic Syndrome

Latest News

  1. ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital

    MOUNTAIN VIEW, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules Capital, Inc.

  2. ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference

    MOUNTAIN VIEW, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan

  3. ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference

    MOUNTAIN VIEW, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper

  4. VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA Associated Vasculitis

    Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity Improved

  5. ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA-Associated Vasculitis

    -- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --   -- Significantly reduced glucocorticoid toxicity -- --

  6. Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)

    -- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2) Inhibition in the

  7. ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights

    -- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and Drug Administration

  8. ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019

    MOUNTAIN VIEW, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's third quarter 2019 financial results will be released after market close on Monday,

  9. ChemoCentryx to Host R&D Day on October 1, 2019

    MOUNTAIN VIEW, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET in New York City.

  10. ChemoCentryx to Present at Two Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor